 Enlivex Therapeutics Ltd. ENLV, a clinical-stage immunotherapy company, today announced positive final safety and efficacy data from the Companys completed Phase Ib clinical trial in patients with severe sepsis. The final analysis compared the clinical data of 10 patients admitted to the intensive care unit with sepsis who were administered off-the-shelf AllocetraTM Allocetra-OTS upon their admission, with 37 patients who were matched controls matched by age, gender, Sequential Organ Failure Assessment SOFA score, and infection source who received only the standard of care treatment at the same hospital during 2014-2019 but did not receive Allocetra-OTS. 